[1]
|
Suster, D.I. and Mino-Kenudson, M. (2020) Molecular Pathology of Primary Non-Small Cell Lung Cancer. Archives of Medical Research, 51, 784-798. https://doi.org/10.1016/j.arcmed.2020.08.004
|
[2]
|
郑荣寿, 孙可欣, 张思维, 曾红梅, 邹小农, 陈茹, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
[3]
|
Zhang, Y.L., Yuan, J.Q., Wang, K.F., Fu, X.H., Han, X.R., Threapleton, D., et al. (2016) The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Oncotarget, 7, 78985-78993. https://doi.org/10.18632/oncotarget.12587
|
[4]
|
Yano, S., Takeuchi, S., Nakagawa, T. and Yamada, T. (2012) Ligand-Triggered Resistance to Molecular Targeted Drugs in Lung Cancer: Roles of Hepatocyte Growth Factor and Epidermal Growth Factor Receptor Ligands. Cancer Science, 103, 1189-1194. https://doi.org/10.1111/j.1349-7006.2012.02279.x
|
[5]
|
王莉洁, 梁志欣, 喻航, 陈良安. 肺癌的驱动基因与靶向治疗研究进展[J]. 国际呼吸杂志, 2017, 37(4): 297-301.
|
[6]
|
Gao, J., Li, H.R., Jin, C., Jiang, J.H. and Ding, J.Y. (2019) Strategies to Overcome Acquired Resistance to EGFR TKI in the Treatment of Non-Small Cell Lung Cancer. Clinical and Translational Oncology, 21, 1287-1301.
https://doi.org/10.1007/s12094-019-02075-1
|
[7]
|
Wu, S.G. and Shih, J.Y. (2018) Management of Acquired Resistance to EGFR TKI-Targeted Therapy in Advanced Non-Small Cell Lung Cancer. Molecular Cancer, 17, Article No. 38. https://doi.org/10.1186/s12943-018-0777-1
|
[8]
|
Wang, Z., Zhou, P.U. and Li, G. (2016) Bevacizumab to Combat EGFR-TKI Resistance in a Patient with Advanced Non-Small Cell Lung Cancer Harboring an EGFR Mutation: A Case Report. Oncology Letters, 12, 356-360.
https://doi.org/10.3892/ol.2016.4574
|
[9]
|
Yoshioka, H., Shimokawa, M., Seto, T., Morita, S., Yatabe, Y., Okamoto, I., et al. (2019) Final Overall Survival Results of WJTOG3405, a Randomized Phase III Trial Comparing Gefitinib versus Cisplatin with Docetaxel as the First-Line Treatment for Patients with Stage IIIB/IV or Postoperative Recurrent EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Annals of Oncology, 30, 1978-1984. https://doi.org/10.1093/annonc/mdz399
|
[10]
|
Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., et al. (2015) Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib versus Chemotherapy as First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (OPTIMAL, CTONG-0802). Annals of Oncology, 26, 1877-1883.
https://doi.org/10.1093/annonc/mdv276
|
[11]
|
Yang, J.C., Sequist, L.V., Zhou, C., Schuler, M., Geater, S.L., Mok, T., et al. (2016) Effect of Dose Adjustment on the Safety and Efficacy of Afatinib for EGFR Mutation-Positive Lung Adenocarcinoma: Post Hoc Analyses of the Randomized LUX-Lung 3 and 6 Trials. Annals of Oncology, 27, 2103-2110. https://doi.org/10.1093/annonc/mdw322
|
[12]
|
Mok, T.S., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., et al. (2021) Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs, 81, 257-266.
https://doi.org/10.1007/s40265-020-01441-6
|
[13]
|
Tripathi, S.K., Pandey, K., Rengasamy, K.R.R. and Biswal, B.K. (2020) Recent Updates on the Resistance Mechanisms to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Resistance Reversion Strategies in Lung Cancer. Medicinal Research Reviews, 40, 2132-2176. https://doi.org/10.1002/med.21700
|
[14]
|
Ramalingam, S.S., Vansteenkiste, J., Planchard, D., Cho, B.C., Gray, J.E., Ohe, Y., et al. (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 382, 41-50.
https://doi.org/10.1056/NEJMoa1913662
|
[15]
|
Wu, Y.L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., et al. (2020) Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine, 383, 1711-1723.
https://doi.org/10.1056/NEJMoa2027071
|
[16]
|
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E. and Tiseo, M. (2019) Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. British Journal of Cancer, 121, 725-737.
https://doi.org/10.1038/s41416-019-0573-8
|
[17]
|
Chikaishi, Y., Kanayama, M., Taira, A., Nabe, Y., Shinohara, S., Kuwata, T., et al. (2018) Effect of Erlotinib plus Bevacizumab on Brain Metastases in Patients with Non-Small Cell Lung Cancer. Annals of Translational Medicine, 6, 401. https://doi.org/10.21037/atm.2018.09.33
|
[18]
|
Nagasaka, M., Zhu, V.W., Lim, S.M., Greco, M., Wu, F. And Ou, S.I. (2021) Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors for Advanced EGFR + NSCLC. Journal of Thoracic Oncology, 16, 740-763. https://doi.org/10.1016/j.jtho.2020.11.028
|
[19]
|
Yun, J., Lee, S.H., Kim, S.Y., Jeong, S.Y., Kim, J.H., Pyo, K.H. et al. (2020) Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discovery, 10, 1194-1209. https://doi.org/10.1158/2159-8290.CD-20-0116
|
[20]
|
周振兴, 宋军民, 陈姬华, 吴强. 贝伐珠单抗在肿瘤治疗中的应用研究进展[J]. 药学进展, 2015, 39(7): 525-532.
|
[21]
|
徐萍, 李红梅. 贝伐珠单抗在非小细胞肺癌中的应用进展[J]. 中国肺癌杂志, 2017, 20(4): 272-277.
|
[22]
|
Garcia, J., Hurwitz, H.I., Sandler, A.B., et al. (2020) Bevacizumabin Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook. Cancer Treatment Reviews, 86, Article ID: 102017.
https://doi.org/10.1016/j.ctrv.2020.102017
|
[23]
|
Jiang, T., Li, A., Su, C., Li, X., Zhao, C., Ren, S., et al. (2017) Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR-TKI Resistance in NSCLC Patients. Oncotarget, 8, 62648-62657.
https://doi.org/10.18632/oncotarget.16061
|
[24]
|
Yamamoto, N., Seto, T., Nishio, M., Goto, K., Okamoto, I., Yamanaka, T., et al. (2018) Erlotinib plus Bevacizumab (EB) versus Erlotinib Alone (E) as First-Line Treatment for Advanced EGFR Mutation-Positive Non-Squamous Non-Small-Cell Lung Cancer (NSCLC): Survival Follow-Up Results of JO25567. Journal of Clinical Oncology, 36, 9007. https://doi.org/10.1200/JCO.2018.36.15_suppl.9007
|
[25]
|
Maemondo, M., Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., et al. (2020) NEJ026: Final Overall Survivalanalysis of Bevacizumab plus Erlotinib Treatment for NSCLCpatients Harboringactivating EGFR-Mutations. Journal of Clinical Oncology, 38, 9506. https://doi.org/10.1200/JCO.2020.38.15_suppl.9506
|
[26]
|
Yamamoto, N., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., et al. (2021) Erlotinib plus Bevacizumab vs Erlotinib Monotherapy as First-Line Treatment for Advanced EGFR Mutation-Positive Non-Squamous Non-Small-Cell Lung Cancer: Survival Follow-up Results of the Randomized JO25567 Study. Lung Cancer, 151, 20-24.
https://doi.org/10.1016/j.lungcan.2020.11.020
|
[27]
|
Yu, H.A., Schoenfeld, A.J., Makhnin, A., Kim, R., Rizvi, H., Tsui, D., et al. (2020) Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. JAMA Oncology, 6, 1048-1054. https://doi.org/10.1001/jamaoncol.2020.1260
|
[28]
|
Zhou, Q., Xu, C.R., Cheng, Y., Liu, Y.P., Chen, G.Y., Cui, J.W., et al. (2021) Bevacizumab plus Erlotinib in Chinese Patients with Untreated, EGFRmutated, Advanced NSCLC (ARTEMISCTONG1509): A Multicenter Phase 3 Study. Cancer Cell, 39, 1279-1291.E3. https://doi.org/10.1016/j.ccell.2021.07.005
|
[29]
|
Nakagawa, K., Garon, E.B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., et al. (2019) Ramucirumab plus Erlotinib in Patients with Untreated, EGFR-Mutated, Advanced Non-Small-Cell Lung Cancer (RELAY): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 1655-1669.
https://doi.org/10.1016/S1470-2045(19)30634-5
|